Human Molecular Genetics, 2001, Vol. 10, No. 21 2425-2435
© 2001 Oxford University Press
Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington’s disease (HD) transgenic mice and HD patients
Division of Medical and Molecular Genetics, GKT School of Medicine, King’s College London, UK, 1Max Planck Institute for Molecular Genetics, Dahlem, Berlin, Germany and 2Imperial Cancer Research Fund, London, UK
Huntington’s disease (HD) is a progressive neurological disorder caused by a CAG/polyglutamine repeat expansion. We have previously generated the R6/2 mouse model that expresses exon 1 of the human HD gene containing CAG repeats in excess of 150. These mice develop a progressive neurological phenotype with a rapid onset and progression. We show here that it is impossible to establish fibroblast lines from these mice at 12 weeks of age, whilst this can be achieved without difficulty at 6 and 9 weeks. Cultures derived from mice at 12 weeks contained a high frequency of dysmorphic cells, including cells with an aberrant nuclear morphology and a high frequency of micronuclei and large vacuoles. All of these features were also present in a line derived from a juvenile HD patient. Fibroblast lines derived from R6/2 mice and from HD patients were found to have a high frequency of multiple centrosomes which could account for all of the observed phenotypes including a reduced mitotic index, high frequency of aneuploidy and persistence of the midbody. We were unable to detect large insoluble polyglutamine aggregates in either the mouse or human lines. We have identified a novel progressive HD pathology that occurs in cells of non-central nervous system origin. An investigation of the pathological consequences of the HD mutation in these cells will provide insight into cellular basis of the disease.
+ To whom correspondence should be addressed at: Division of Medical and Molecular Genetics, GKT School of Medicine, 8th Floor Guy’s Tower, Guy’s Hospital, London SE1 9RT, UK. Tel: +44 020 7955 4485; Fax: +44 020 7955 4444; Email: gillian.bates@kcl.ac.ukPresent address: Fabien Bertaux, Genoway, Lyon, France
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. B.D. Clabough and S. O. Zeitlin Deletion of the triplet repeat encoding polyglutamine within the mouse Huntington's disease gene results in subtle behavioral/motor phenotypes in vivo and elevated levels of ATP with cellular senescence in vitro Hum. Mol. Genet., February 15, 2006; 15(4): 607 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kristiansen, M. J. Messenger, P.-C. Klohn, S. Brandner, J. D. F. Wadsworth, J. Collinge, and S. J. Tabrizi Disease-related Prion Protein Forms Aggresomes in Neuronal Cells Leading to Caspase Activation and Apoptosis J. Biol. Chem., November 18, 2005; 280(46): 38851 - 38861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Benn, C. Landles, H. Li, A. D. Strand, B. Woodman, K. Sathasivam, S.-H. Li, S. Ghazi-Noori, E. Hockly, S. M.N.N. Faruque, et al. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease Hum. Mol. Genet., October 15, 2005; 14(20): 3065 - 3078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bjorkqvist, M. Fex, E. Renstrom, N. Wierup, A. Petersen, J. Gil, K. Bacos, N. Popovic, J.-Y. Li, F. Sundler, et al. The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis Hum. Mol. Genet., March 1, 2005; 14(5): 565 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Lievens, T. Rival, M. Iche, H. Chneiweiss, and S. Birman Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila Hum. Mol. Genet., March 1, 2005; 14(5): 713 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, D. L. Smith, A. B. Meriin, S. Engemann, D. E. Russel, M. Roark, S. L. Washington, M. M. Maxwell, J. L. Marsh, L. M. Thompson, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo PNAS, January 18, 2005; 102(3): 892 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Hay, K. Sathasivam, S. Tobaben, B. Stahl, M. Marber, R. Mestril, A. Mahal, D. L. Smith, B. Woodman, and G. P. Bates Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach Hum. Mol. Genet., July 1, 2004; 13(13): 1389 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hockly, V. M. Richon, B. Woodman, D. L. Smith, X. Zhou, E. Rosa, K. Sathasivam, S. Ghazi-Noori, A. Mahal, P. A. S. Lowden, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease PNAS, February 18, 2003; 100(4): 2041 - 2046. [Abstract] [Full Text] [PDF]
|
|